XML 51 R33.htm IDEA: XBRL DOCUMENT v3.25.0.1

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

12 Months Ended

Dec. 31, 2024

Revenue from Contract with Customer [Abstract]

Schedule of Changes in Contract Assets and Contract Liabilities

The following table summarized the changes in the contract asset and liability balances for the year ended December 31, 2024:

Dollars in thousands			Total
Contract Asset
Contract asset, January 1, 2024			$	9,233
Transferred to trade receivable from contract asset included in beginning of the year contract asset			(9,233)
Contract asset, net of transferred to trade receivables on contracts during the period			6,146
Contract asset, December 31, 2024			$	6,146
Contract Liability
Contract liability, January 1, 2024			$	16,252
Recognition of revenue included in beginning of year contract liability			(10,307)
Contract liability, acquired with Acclarent			3,984
Contract liability, net of revenue recognized on contracts during the period			9,874
Foreign currency translation			(134)
Contract liability, December 31, 2024			$	19,669

Schedule of Disaggregation of Revenue

The following table presents revenues disaggregated by the major sources of revenues for years-ended December 31, 2024, 2023, and 2022 (dollar amounts in thousands):

												Year Ended December 31, 2024			Year Ended December 31, 2023			Year Ended December 31, 2022
Neurosurgery												$	803,816		$	818,101		$	794,017
Instruments												204,177			203,617			192,679
ENT(1)(2)												135,643			37,275			32,868
Total Codman Specialty Surgical												1,143,636			1,058,993			1,019,564
Wound Reconstruction and Care(3)(4)												350,565			373,986			406,689
Private Label												116,326			108,594			131,413
Total Tissue Technologies												466,891			482,580			538,102
Total revenue												$	1,610,527		$	1,541,573		$	1,557,666

(1) See Note 4. Acquisitions and Divestitures for details surrounding the acquisition of Acclarent on April 1, 2024.

(2) Prior period revenues included within our instruments business have been reclassified under the ENT business.

(3) See Note 4. Acquisitions and Divestitures for details surrounding the SIA acquisition on December 7, 2022.

(4) See Note 4. Acquisitions and Divestitures for details surrounding the sale of the Company’s non-core traditional wound care (“TWC”) business on August 31, 2022.

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration